Combining semaglutide with cagrilintide (known as CagriSema) offers enhanced synergistic benefits for weight loss, blood sugar control, and blood pressure reduction by targeting two distinct hormonal satiety pathways in the brain and gut simultaneously. 

Core Benefits

• Superior Weight Loss: Clinical trials (such as the REDEFINE 1 Phase 3 Trial via New England Journal of Medicine) demonstrate that the combination yields average body weight reductions of 20% or more, outperforming either semaglutide or cagrilintide used alone.

• Enhanced Blood Sugar Control: For patients with type 2 diabetes, CagriSema provides significantly greater reductions in glycated hemoglobin (HbA1c) and fasting glucose compared to semaglutide monotherapy. 

• Blood Pressure and Cardiometabolic Improvement: Treatment leads to meaningful reductions in systolic blood pressure, helping patients with obesity-related or resistant hypertension lower or discontinue other blood pressure medications. 

• Complementary Mechanisms: Semaglutide mimics GLP-1 to stimulate insulin and suppress appetite via the hypothalamus, while cagrilintide mimics amylin to delay gastric emptying and act on hindbrain satiety pathways, creating a non-duplicative, powerful stop-signal for hunger.